AUTHORS
Josh A Kent, B.A., Anouchka P. Laurent, PhD2, Ryan D. Najac3, Laura Quevedo, PhD4, Ruth A. Alonso5, Barbara Pro, MD6, Seda S. Tolu, MD7, Alejandro Gru, MD8, Larisa J. Geskin, MD9, Teresa Palomero, PhD10
AFFILIATIONS
1 Columbia University Irving Medical Center, New York, New York, United States
2 Columbia University Irving Medical Center, New York, New York, United States
3 Columbia University Institute for Cancer Genetics, New York, United States
4 Columbia University Institute for Cancer Genetics, New York, United States
5 Columbia University Institute for Cancer Genetics, New York, United States
6 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States
7 Columbia Herbert Irving Comprehensive Cancer Center, New York, New York, United States
8 Columbia University Irving Medical Center, New York, New York, United States
9 Columbia University Irving Medical Center, New York, New York, United States
10 Columbia University Institute for Cancer Genetics, New York, United States
ABSTRACT
Introduction: Cutaneous T-cell lymphomas (CTCL) are skin-homing mature T-cell neoplasms. Sézary syndrome (SS), the leukemic form, is aggressive and largely incurable, with 5-year overall survival near 30% (Scarisbrick, JCO 2015). Constitutive JAK/STAT activation via STAT3/STAT5 is a recurrent oncogenic driver across cutaneous and peripheral T-cell lymphoma (PTCL) (Park, Blood 2021), yet single-agent JAK inhibition produces responses that are frequently incomplete, biomarker-dependent, and non-durable. In a biomarker-stratified phase 2 study of ruxolitinib, benefit was enriched among patients with activating JAK/STAT mutations (53%) or phospho-STAT3 positivity (45%) but was rare in their absence (13%), and only 1 of 7 patients with mycosis fungoides (MF) benefited (Moskowitz, Blood 2021). This underscores the need to identify pathways that cooperate with JAK/STAT inhibition. The paralogous acetyltransferases CBP (CREBBP) and p300 (EP300) drive enhancer- and promoter-associated transcriptional programs, and the oral CBP/p300 bromodomain inhibitor inobrodib (CCS1477) induced responses in 3 of 4 patients with PTCL in early-phase testing (Campbell, Blood 2023). We previously showed that CBP/p300 inhibition sensitizes JAK2-mutant myeloproliferative neoplasms (MPN) to JAK inhibitors, converging transcriptionally on MYC (Bertulfo, Blood 2024). We therefore asked whether CBP/p300 and JAK inhibitors synergize in CTCL.
Methods: Four CBP/p300 inhibitors (A-485, PF-CBP1, SGC-CBP30, CCS1477) and four JAK inhibitors (ruxolitinib, pacritinib, momelotinib, fedratinib) were tested as single agents across a panel of MF- and SS-derived CTCL lines (HuT78, SeZ4, SeAx, MyLa, PB2B, HH). CCS1477 was then combined with ruxolitinib or pacritinib, and synergy was quantified by combination index (CI). Apoptosis was assessed by Annexin V staining. Combinations were tested in 3 primary CTCL/SS patient samples collected under an IRB-approved protocol. MYC mRNA and protein were measured by qPCR and immunoblot. CREBBP and EP300 mutation, expression, and CRISPR dependency in CTCL lines were analyzed in DepMap (Public 26Q1).
Results: Single-agent CBP/p300 and JAK inhibitors reduced viability with variable potency; CCS1477 was among the most active CBP/p300 inhibitors, with greatest single-agent activity in HuT78 and HH. CCS1477 synergized with ruxolitinib in 5 of 6 lines: HuT78 (CI 0.19), MyLa (0.20), SeZ4 (0.22), SeAx (0.37), and PB2B (0.75), but not HH (2.07). CCS1477 plus pacritinib was synergistic-to-additive across nearly the entire panel (CI 0.18-0.98). Both combinations markedly increased the Annexin V-positive fraction over either single agent in HuT78 and SeZ4. In 3 primary CTCL/SS patient samples, CCS1477 plus ruxolitinib was synergistic in all 3 (CI 0.08, 0.50, 0.64) and CCS1477 plus pacritinib in 2 of 3, confirming activity in primary malignant cells. The strongest synergy (CI 0.08) occurred in a sample from a patient with SS and a concurrent JAK2-V617F MPN. Mechanistically, the combination converged on MYC: in HuT78, CCS1477 plus ruxolitinib reduced MYC mRNA to 13% of control, well below either agent alone (ruxolitinib 74%; CCS1477 87%), with a concomitant decrease in MYC protein.
Conclusions: Combined CBP/p300 and JAK inhibition is robustly synergistic across MF- and SS-derived cell lines and primary patient samples, induces apoptosis, and converges on suppression of MYC, mirroring the mechanism we described in JAK2-mutant MPN. Because synergy occurs independently of CREBBP status, this combination may be broadly applicable across CTCL genotypes. Inobrodib is already in early-phase trials in T-cell lymphoma and JAK inhibitors are in routine clinical use, positioning this combination for rapid clinical translation in a disease with an urgent need for more effective therapy.
DISCLOSURES
Josh A Kent, B.A.: No relevant conflicts of interest to declare.